The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury: a translational in vitro study

  1. Amy Louise Ball
  2. Carol Elizabeth Jolly
  3. Mark G Lennon
  4. Jonathan J Lyon
  5. Ana Alfirevic
  6. Amy E Chadwick  Is a corresponding author
  1. University of Liverpool, United Kingdom
  2. GlaxoSmithKline, United Kingdom

Abstract

Background: Evidence supports an important link between mitochondrial DNA (mtDNA) variation and adverse drug reactions such as idiosyncratic drug-induced liver injury (iDILI). Here, we describe the generation of HepG2-derived transmitochondrial cybrids, to investigate the impact of mtDNA variation on mitochondrial (dys)function and susceptibility to iDILI. This study created 10 cybrid cell lines, each containing distinct mitochondrial genotypes of haplogroup H or haplogroup J backgrounds.

Methods: HepG2 cells were depleted of mtDNA to make rho zero cells, before the introduction of known mitochondrial genotypes using platelets from healthy volunteers (n=10), thus generating 10 transmitochondrial cybrid cell lines. The mitochondrial function of each was assessed at basal state and following treatment with compounds associated with iDILI; flutamide, 2-hydroxyflutamide, and tolcapone, and their less toxic counterparts bicalutamide and entacapone utilising ATP assays and extracellular flux analysis.

Findings: Whilst only slight variations in basal mitochondrial function were observed between haplogroups H and J, haplogroup-specific responses were observed to the mitotoxic drugs. Haplogroup J showed increased susceptibility to inhibition by flutamide, 2-hydroxyflutamide and tolcapone, via effects on selected mitochondrial complexes (I and II), and an uncoupling of the respiratory chain.

Conclusions: This study demonstrates that HepG2 transmitochondrial cybrids can be created to contain the mitochondrial genotype of any individual of interest. This provides a practical and reproducible system to investigate the cellular consequences of variation in the mitochondrial genome, against a constant nuclear background. Additionally, the results show that inter-individual variation in mitochondrial haplogroup may be a factor in determining sensitivity to mitochondrial toxicants.

Funding: This work was supported by the Centre for Drug Safety Science supported by the Medical Research Council, United Kingdom (Grant Number G0700654); and GlaxoSmithKline as part of an MRC-CASE studentship (grant number MR/L006758/1).

Data availability

Source Data files have been provided for Figures 2, 3, 4, 5, 6 and supplementary figures s1, s3, s4, s5, s6

The following previously published data sets were used

Article and author information

Author details

  1. Amy Louise Ball

    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    Amy Louise Ball, holds a grant from GlaxoSmithKline (GSK) for this work. The author has no other competing interests to declare..
  2. Carol Elizabeth Jolly

    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    Carol Elizabeth Jolly, salary funded by Janssen Pharmaceutical, paid to University of Liverpool. The author has no other competing interests to declare..
  3. Mark G Lennon

    GlaxoSmithKline, Ware, United Kingdom
    Competing interests
    Mark G Lennon, is an employee of GlaxoSmithKline (GSK)..
  4. Jonathan J Lyon

    GlaxoSmithKline, Ware, United Kingdom
    Competing interests
    Jonathan J Lyon, is an employee of GlaxoSmithKline (GSK). Unpaid role as a member of the Investigative Toxicology Leaders Forum (ITLF) representing GSK on this group. Provides unpaid consultation to Cambridge University in areas of drug development. The author has no other competing interests to declare..
  5. Ana Alfirevic

    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    Ana Alfirevic, holds a grant from GlaxoSmithKline (GSK) for this work. The author has no other competing interests to declare..
  6. Amy E Chadwick

    Department Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    For correspondence
    Aemercer@liverpool.ac.uk
    Competing interests
    Amy E Chadwick, holds a grant from GlaxoSmithKline (GSK) for this work and received other funding from Janssen in 2017-2020 (paid directly to University of Liverpool). The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7399-8655

Funding

Medical Research Council (Centre for Drug Safety Science,G0700654)

  • Carol Elizabeth Jolly
  • Amy E Chadwick

GlaxoSmithKline (MRC-CASE studentship,grant number MR/L006758/1))

  • Amy Louise Ball

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This work with human material in this project was approved by the North West of England Research Ethics Committee and all participants gave written informed consent and consent to publish. All procedures were in accordance with the ethical standards of the North West of England Research Ethics Committee (Cell Archive of HLA Typed Healthy Volunteers (HLA), CRN ID 7787, IRAS ID: 15623) with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Copyright

© 2023, Ball et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 861
    views
  • 128
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amy Louise Ball
  2. Carol Elizabeth Jolly
  3. Mark G Lennon
  4. Jonathan J Lyon
  5. Ana Alfirevic
  6. Amy E Chadwick
(2023)
The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury: a translational in vitro study
eLife 12:e78187.
https://doi.org/10.7554/eLife.78187

Share this article

https://doi.org/10.7554/eLife.78187

Further reading

    1. Medicine
    2. Neuroscience
    Emily M Adamic, Adam R Teed ... Sahib Khalsa
    Research Article

    Interactions between top-down attention and bottom-up visceral inputs are assumed to produce conscious perceptions of interoceptive states, and while each process has been independently associated with aberrant interoceptive symptomatology in psychiatric disorders, the neural substrates of this interface are unknown. We conducted a preregistered functional neuroimaging study of 46 individuals with anxiety, depression, and/or eating disorders (ADE) and 46 propensity-matched healthy comparisons (HC), comparing their neural activity across two interoceptive tasks differentially recruiting top-down or bottom-up processing within the same scan session. During an interoceptive attention task, top-down attention was voluntarily directed towards cardiorespiratory or visual signals. In contrast, during an interoceptive perturbation task, intravenous infusions of isoproterenol (a peripherally-acting beta-adrenergic receptor agonist) were administered in a double-blinded and placebo-controlled fashion to drive bottom-up cardiorespiratory sensations. Across both tasks, neural activation converged upon the insular cortex, localizing within the granular and ventral dysgranular subregions bilaterally. However, contrasting hemispheric differences emerged, with the ADE group exhibiting (relative to HCs) an asymmetric pattern of overlap in the left insula, with increased or decreased proportions of co-activated voxels within the left or right dysgranular insula, respectively. The ADE group also showed less agranular anterior insula activation during periods of bodily uncertainty (i.e. when anticipating possible isoproterenol-induced changes that never arrived). Finally, post-task changes in insula functional connectivity were associated with anxiety and depression severity. These findings confirm the dysgranular mid-insula as a key cortical interface where attention and prediction meet real-time bodily inputs, especially during heightened awareness of interoceptive states. Furthermore, the dysgranular mid-insula may indeed be a ‘locus of disruption’ for psychiatric disorders.

    1. Medicine
    Yanling Huang, Haocong Mo ... Geyang Xu
    Research Article

    Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Molecular biology techniques revealed the expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 (Piezo1 IntL-CKO) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high-fat diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These experimental results suggest a previously unknown regulatory mechanism for GLP-1 production in L cells, which could offer new insights into diabetes treatments.